Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2026-04-01Clinical Trial Update: Development of Digital Biomarkers in Multiple Sclerosis: Validation Study 2
A clinical trial evaluating digital biomarkers for multiple sclerosis has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2026-03-30Clinical Trial Update: Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years (STOP-I-SEP) [Phase 3]
Phase 3 clinical trial evaluating withdrawal of disease-modifying therapies in inactive secondary progressive multiple sclerosis patients ov…
-
CLINICAL_TRIALS withdrawal · 2026-03-30Clinical Trial Update: This is an Open-Label Study to Assess the Safety and Efficacy of GC012F in Patients With Multiple Sclerosis [EARLY_Phase 1]
An open-label early Phase 1 trial evaluating GC012F for safety and efficacy in patients with multiple sclerosis has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2026-03-24Clinical Trial Update: Context- and Terrain-aware Gait Analysis
A University of Leeds clinical trial evaluating context- and terrain-aware gait analysis in Parkinson's disease, dementia, and related condi…
-
CLINICAL_TRIALS withdrawal · 2026-02-03Clinical Trial Update: A Study of RD06-04 in Patients With Active Autoimmune Diseases [EARLY_Phase 1]
A early Phase 1 study of RD06-04 in active autoimmune diseases has been withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2025-12-04Clinical Trial Update: Managed Access Program (MAP) for Patients Diagnosed With Secondary Progressive Multiple Sclerosis With Active Disease
The clinical trial update confirms that the Novartis-sponsored Managed Access Program for patients with secondary progressive multiple scler…
-
CLINICAL_TRIALS withdrawal · 2025-12-02Clinical Trial Update: A Lactation Study in Women Receiving Treatment With Ozanimod [Phase 4]
A Phase 4 lactation study of ozanimod (Zeposia) in women receiving treatment has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-10-20Clinical Trial Update: Effect of Alemtuzumab on Microglial Activation Positron Emission Tomography (PET) in Multiple Sclerosis [Phase 1, Phase 2]
Clinical trial update indicates the Phase 1/Phase 2 study of alemtuzumab for multiple sclerosis has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-08-17Clinical Trial Update: A Clinical Trial Evaluating the Safety and Efficacy of Myelin-peptide Loaded tolDC as Treatment for MS [Phase 2]
A Phase 2 trial evaluating myelin-peptide loaded tolerogenic dendritic cells for multiple sclerosis has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-06-05Clinical Trial Update: A Pilot Study to Explore the Role of Gut Flora in Multiple Sclerosis
A pilot study investigating the role of gut flora in Multiple Sclerosis has been withdrawn.
-
EMA withdrawal · 2025-04-30EMA Withdrawn: Extavia (interferon beta-1b) — Novartis Europharm Limited
The European Medicines Agency has withdrawn Extavia (interferon beta-1b) for multiple sclerosis, with Novartis Europharm Limited as the mark…
-
CLINICAL_TRIALS withdrawal · 2025-03-10Clinical Trial Update: Validity and Reliability of the Modified Four Square Step Test in Multiple Sclerosis Patients
The clinical trial assessing the validity and reliability of the Modified Four Square Step Test in people with Multiple Sclerosis has been w…
-
CLINICAL_TRIALS withdrawal · 2024-11-27Clinical Trial Update: Comparison of Vigorous Versus Low Intensity Cool Room Treadmill Training in People with Multiple Sclerosis [NA]
Clinical trial evaluating vigorous versus low-intensity cool-room treadmill training in people with Multiple Sclerosis has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2024-08-09Clinical Trial Update: Assessing the Cognitive Benefits of Ozanimod and Their Brain-Biomarkers in MS [Phase 4]
The Phase 4 clinical trial evaluating cognitive benefits of ozanimod in multiple sclerosis, including brain biomarker analyses, has been wit…
-
CLINICAL_TRIALS withdrawal · 2024-01-23Clinical Trial Update: A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis [Phase 4]
A Phase 4 clinical trial evaluating ocrelizumab for leptomeningeal inflammation in multiple sclerosis has been withdrawn.
-
EMA withdrawal · 2023-12-22EMA Revoked: Dimethyl fumarate Teva (dimethyl fumarate) — Teva GmbH
EMA revoked the marketing authorization for Teva's dimethyl fumarate product.
-
EMA withdrawal · 2023-12-22EMA Revoked: Dimethyl fumarate Accord (dimethyl fumarate) — Accord Healthcare S.L.U.
EMA revoked the marketing authorization for Dimethyl fumarate Accord for multiple sclerosis indications.
-
CLINICAL_TRIALS withdrawal · 2023-08-23Clinical Trial Update: The Effects of Ethyl-Alpha-Guanido-Methyl Ethanoate on Skin Reactions From Glatiramer Acetate Injections [Phase 4]
A Phase 4 trial investigating the effects of a compound on skin reactions from glatiramer acetate injections was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2022-04-27Clinical Trial Update: To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS [Phase 3]
Phase 3 trial assessing arbaclofen ER tablets vs placebo on sperm parameters in male MS patients was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2018-07-18Clinical Trial Update: The Effects of Different Medical Marijuana Strains on Motor and Cognitive Function in People With Multiple Sclerosis [Phase 2, Phase 3]
A clinical trial evaluating the effects of different medical marijuana strains on motor and cognitive function in people with Multiple Scler…
-
EMA withdrawal · 2018-06-28EMA Withdrawn: Zinbryta (daclizumab) — Biogen Idec Ltd
The EMA has withdrawn Zinbryta (daclizumab) from the market for multiple sclerosis.
-
CLINICAL_TRIALS withdrawal · 2018-05-24Clinical Trial Update: Drug Risk Aversion Calculator Use to Facilitate MS Patient Self-efficacy [NA]
A Duke University clinical trial evaluating a Drug Risk Aversion Calculator for facilitating multiple sclerosis patient self-efficacy has be…
-
CLINICAL_TRIALS withdrawal · 2018-04-12Clinical Trial Update: Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event. [Phase 4]
Phase 4 trial evaluating induction therapy with a single high-dose intravenous methotrexate with leucovorin rescue prior to AVONEX treatment…
-
CLINICAL_TRIALS withdrawal · 2018-04-12Clinical Trial Update: Progression of Cognitive and Physical Symptoms in Multiple Sclerosis
The clinical trial NCT00922831 evaluating progression of cognitive and physical symptoms in multiple sclerosis has been withdrawn.
-
EMA withdrawal · 2018-02-06EMA Application withdrawn: Qizenday — Medday Pharmaceuticals
EMA withdrawal of the Qizenday application from Medday Pharmaceuticals for multiple sclerosis.